

July 3, 2017

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

Scrip code: 532531

The National Stock Exchange of India Limited

Exchange Plaza, Bandra-Kurla Complex
Bandra (E) Mumbai - 400 051

Scrip code: STAR

Dear Sirs,

Sub: Press Release


Please find attached press release issued by the Company titled:

**“Strides Shasun receives USFDA Approval for
Promethazine Hydrochloride Tablets”**

Thanks & Regards,
For **STRIDES SHASUN LIMITED**



Manjula Ramamurthy
Company Secretary





Press Release

Monday, July 3, 2017

Strides Shasun Limited
(Formerly Strides Arcolab Limited)
Strides House, Bannerghatta Road,
Bangalore – 560076.

Strides Shasun receives USFDA Approval For Promethazine Hydrochloride Tablets

Product to be manufactured at the Bangalore facility

Bangalore, July 3, 2017 Strides Shasun Limited today announced that it has received approval from the United States Food & Drug Administration (USFDA) for **Promethazine Hydrochloride Tablets USP, 12.5 mg, 25 mg, and 50 mg.**

According to IMS data, the US market for Promethazine Hydrochloride Tablets USP, 12.5 mg, 25 mg, and 50 mg is approximately USD 17 Million. The product will be manufactured at the Company's flagship facility at Bangalore and marketed by Strides Pharma Inc. in the US Market.


About Promethazine Hydrochloride Tablets

Promethazine Hydrochloride Tablet is used to prevent and treat nausea and vomiting related to certain conditions. It is also used to treat allergy symptoms such as rash, itching, and runny nose.

About Strides Shasun Limited

Strides Shasun, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a vertically integrated global pharmaceutical Company headquartered in Bangalore. The Company has four business verticals, viz., Regulated Markets, Emerging Markets, Institutional Business and Active Pharmaceutical Ingredients.

The Company has global manufacturing foot print with 8 manufacturing facilities spread across three continents including 6 US FDA approved facilities and 2 facilities for the emerging markets. The Company has three dedicated R&D facilities in India with global filing capabilities and a strong commercial footprint across 85 countries. Additional information is available at the Company's website at www.stridesarco.com



For further information, please contact:

<u>Strides Shasun</u> Shashank Sinha, Managing Director +91 80 6784 0335 Vikesh Kumar: +91 80 6784 0827 Kannan. N: +91 98450 54745 Sandeep Baid: +91 80 6784 0791	<u>PR Consultancy</u> Fortuna PR K Srinivas Reddy: +91 9000527213 srinivas@fortunapr.com K Priya: +91 9535425418 priya@fortunapr.com
---	--

